Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 14/20 | 0.57 |
| ▸ | GSK3B | P49841 | 8/20 | 0.57 |
| ▸ | SRC | P12931 | 7/20 | 0.57 |
| ▸ | AURKA | O14965 | 14/20 | 0.50 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | AURKC | Q9UQB9 | 3/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19990409 | 0.89 | AURKB (0.49) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL19990549 | 0.87 | AURKB (0.61) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL29487458 | 0.86 | AURKA (0.61) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL18165846 | 0.86 | AURKA (0.61) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL29487474 | 0.86 | AURKA (0.51) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL18165868 | 0.86 | AURKA (0.51) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL19990520 | 0.85 | AURKA (0.50) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL19990508 | 0.84 | AURKB (0.63) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL18154682 | 0.84 | AURKB (0.63) | AURKBGSK3BSRCAURKAPLK4 | |
| SCHEMBL29487447 | 0.84 | PLK4 (0.61) | AURKBGSK3BSRCAURKAPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| US-20200383990-A1 | METHODS OF TREATING CANCER WITH PLK4 INHIBITORS | LUDWI INSTITUTE FOR CANCER RESEARCH LTD. (CH) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | AURKB 28/4885GSK3B 154/4885SRC 1488/4885 |
| US-20200383990-A1 | METHODS OF TREATING CANCER WITH PLK4 INHIBITORS | PLK4, PLK2, PLK3 | AURKB 28/4885GSK3B 154/4885SRC 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.